Tenax Therapeutics, Inc. (NASDAQ: TENX)

TENX-176

Tenax Therapeutics, Inc. (formerly Oxygen Biotherapeutics) is a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market. The company owns the North American rights to develop and commercialize levosimendan, and the United … Continue reading


DelMar Pharmaceuticals (OTC: DMPI)

DMPI-176

DelMar Pharmaceuticals was founded in 2010 to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments. The Company’s lead asset, VAL-083, is currently undergoing clinical trials in the United … Continue reading


ContraFect Corporation (NASDAQ: CFRX)

contrafect-176

ContraFect Corporation is a biotechnology company focused on discovering and developing therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. Due to drug-resistant and newly emerging pathogens, hospital acquired infections are currently the … Continue reading


Medgenics, Inc. (MDGN)

mdgn-176

Medgenics is a medical technology and therapeutics company focused on providing sustained protein therapies. The Company has developed proprietary technology called the Biopump Platform, which uses the patient’s own tissue to continuously produce and deliver the patient’s own protein therapy. … Continue reading


Medicinova (MNOV)

mnov-176

MediciNova, Inc. is a publicly-traded biopharmaceutical company founded upon acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical needs with a commercial focus on the U.S. market. MediciNova’s current strategy is to focus on MN-166 … Continue reading


Fibrocell Science (FCSC)

fcsc-176

Fibrocell Science, Inc. (OTC Bulletin Board: FCSC) is a biotechnology company focused on developing autologous cell therapies for aesthetic, medical and scientific applications. Fibrocell Science is committed to advancing the scientific, medical and commercial potential of autologous skin and tissue, … Continue reading


TONIX Pharmaceuticals (TNXP)

tnxp-176

TONIX is developing innovative prescription medications for challenging disorders of the central nervous system. The Company targets conditions characterized by significant unmet medical need, inadequate existing treatment options, and high dissatisfaction among both patients and physicians. TONIX’s core technology improves … Continue reading


TG Therapeutics (TGTX)

tgtx-176

TG Therapeutics is an innovative, clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of innovative and medically important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. Currently we are developing ublituximab (TGTX-1101), a novel, third … Continue reading


InspireMD, Inc. (NSPR)

inspiremd-176

InspireMD is an innovative medical device company focusing on the development and commercialization of its proprietary stent system technology, MGuard. The company intends to apply its technology to develop products used in interventional cardiology and other vascular procedures. InspireMD’s mission … Continue reading


DARA BioSciences (DARA)

dara-176

DARA is a pharmaceutical development company that acquires promising therapeutic molecules in early stage development. It then expedites development through proof-of-concept in humans for subsequent partnering, sale or out-licensing to large healthcare and pharmaceutical companies. The effective implementation of this … Continue reading


Cipher Pharmaceuticals (DND.TO)

dnd-to-176

Cipher Pharmaceuticals is a drug development company focused on commercializing novel formulations of currently marketed molecules that have been improved through advanced drug delivery technologies. Cipher’s lead compound, CIP-FENOFIBRATE, is marketed in the United States by Kowa Pharmaceuticals America under … Continue reading


Coronado Biosciences

Coronado Biosciences is engaged in the development of novel immunotherapy biologic agents. The Company’s two principal pharmaceutical product candidates in clinical development are: CNDO-201, a biologic for the treatment of autoimmune diseases, such as Crohn’s disease, ulcerative colitis and multiple … Continue reading


22nd Century Group, Inc. (XXII)

XXII-176

Founded in 1998, 22nd Century Limited, LLC (22nd Century) is a plant biotechnology company whose proprietary technology allows for the level of nicotine (and other nicotinic alkaloids) in the tobacco plant to be decreased or increased through genetic engineering and … Continue reading


Ventrus Biosciences (VTUS)

vtus-176

Ventrus is a development stage specialty pharmaceutical company focused on the development of late-stage prescription drugs for gastrointestinal disorders, specifically hemorrhoids, anal fissures and fecal incontinence. There are approximately 12.5 million Americans suffering from hemorrhoids, 7 million from fecal incontinence … Continue reading


Threshold Pharmaceuticals, Inc. (THLD)

thld-176

Threshold is a biotechnology company focused on the discovery and development of therapeutics based on Tumor Hypoxia, a powerful scientific platform that offers broad potential to treat most solid tumors. By selectively targeting tumor cells, we are building a pipeline … Continue reading


Dynavax Technologies Corporation (DVAX)

dvax-176

Dynavax Technologies Corporation is a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious and inflammatory diseases.  Our clinical-stage product candidates include: Phase 3 HEPLISAV ™ Hepatitis B Vaccine Phase 1 Universal Flu Vaccine Phase 1 … Continue reading


Keryx Biopharmaceuticals (KERX)

kerx-176

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer. Keryx is developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the … Continue reading


ZIOPHARM Oncology (ZIOP)

ziop-176

ZIOPHARM Oncology is a biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of cancer drugs. The Company is currently focused on the development of three clinical programs for multiple indications. Palifosfamide (ZIO-201) is a novel molecule … Continue reading


Synthetic Biologics (SYN)

syn-176

Synthetic Biologics (NYSE Amex: SYN) is a biotechnology company focused on the development of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses. Synthetic Biologics is developing, or has partnered the development of, product candidates to treat pulmonary arterial … Continue reading


Alexza Pharmaceuticals, Inc. (ALXA)

alxa-176

Alexza Pharmaceuticals, Inc., a specialty pharmaceutical development stage company, focuses on the research, development, and commercialization of products for the acute treatment of central nervous system conditions. Its technology, Staccato system, vaporizes an excipient-free drug to form a condensation aerosol … Continue reading